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introduction
To make decisions in their clinical practice, clinicians have to
deploy a huge amount of rapidly growing knowledge available in
their areas of specialization. From 1994 to 2001, more than 25 000
articles reporting randomized trials were published. Assessing and
interpreting those results could be a hard task for clinicians trying
to adopt best professional practice. Clinical Practice Guidelines
(CPGs) should clearly set out the scientiﬁc evidence and should
also appraise the likely beneﬁts and harm behind clinical
recommendations. They should be oriented not only towards
improving the health of the patient, but also towards converting
the complexity of the ﬁndings of scientiﬁc research into
recommendations for everyday practice. By achieving this, they
will also enhance the quality of life and outcomes of patients.
ESMO is highly committed to developing such CPGs. The
Guidelines Working Group (GLWG) believes that this is an
important service to its members. In order to better meet the
needs of its members, the ESMO GLWG has tried to adapt and
improve the quality of its guidelines, and has expanded the
participation of multidisciplinary experts in the ﬁeld.
Until 2007, the ESMO GLWG was providing short-sized
clinical recommendations dedicated to medical oncologists.
Eventually, the content of clinical recommendations was
increased in size, and in 2007, it was unanimously decided that
recommendations be developed from ESMO guidelines
discussed at Consensus Conferences (CCs).
Consensus decision-making is a group decision-making
process that seeks the consensus of experts and the fulﬁllment
of objectives. It has its origin in a Latin word literally meaning
feel together.
In this setting, development of guidelines through CCs was
considered a more enriched and integrative approach to
producing better evidence-based CPGs enabling best practice.
Thus far, 10 CCs on various common tumors as well as
supportive treatment [1–3] have been held.
The purpose of ESMO CCs was to develop oncologic
guidelines on the treatment of certain tumors with the aim of
evaluating available scientiﬁc information and improving the
understanding of the key topics. The model of participatory CCs
was based on the expert CC model. In short, the CC chairs start
by inviting acclaimed experts with pan European distribution
and by identifying subtopics regarding each tumor type to be
studied by working groups (WGs). Each WG, represented by a
coordinator, undertakes the task of studying relevant evidence
and providing critical questions and answers pertaining to the
subtopic assigned, followed by formulation of recommendations.
The «question and answer» format was chosen, since it is
considered the most relevant and communicable form to the
practicing oncologist. After this important preparatory work has
been accomplished via electronic communication, all the WGs
meet at the CCs and present and discuss their ﬁndings.
Following this, the writing up of the Consensus document is
delegated to the WGs before being ﬁnalized by the CC chairs
and the ESMO GLWG and Educational Committee.
methodology
ESMO CC standard operating procedures (SOP) are shown in Figure 1.
ESMO CCs organized from 2007 to 2012
From October 2007 to January 2012, 10 CCs were organized
on soft-tissue sarcomas, bone sarcomas, gastrointestinal
stromal tumors (GIST), testicular seminoma and non-
seminoma, non-small-cell and small-cell lung cancer,
colorectal cancer, prostate cancer, lymphomas as well as
antiemetics and communication skills.
CCs were organized under the auspices of ESMO,
Conticanet, Multinational Association of Supportive Care in
Cancer (MASCC), Swiss Cancer League, Eurobonet and San
Salvatore Foundation.
The number of panel members ranged from 23 to 66 and
the number of participated countries from 5 to 22. Almost all
the Conferences had multidisciplinary representation. All the
guidelines derived were published or will be published in
Annals of Oncology [4–17] (Table 1).
perspectives
The ESMO GLWG intends to continue developing ESMO
CPGs through CCs. It believes that this procedure will offer
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Figure 1 ESMO Consensus Conference SOP flowchart.
Table 1. ESMO Consensus Conferences
Date Topic Organizer Chairs Panel
members
No.
countries
Multidisciplinarity Publication
October 2007 Soft tissue sarcomas
GIST
Conticanet P. Casali, J.Y. Blay 45 16 PA, MO, SO, RO [4]
[5]
May 2008 Seminoma
Non-seminoma
ESMO H.J. Schmoll,M.P.
Laguna
66 18 – [6]
[7]
May 2009 Communication skills Swiss, Cancer
League
J. Barth, J. Bensing,
L. Fallowﬁeld,
A. Kiss, D. Razavi,
F. Stiefel
45 5 – [8]
June 2009 Antiemetics MASCC/ESMO – 23 10 CM, ON, PHARM,
MP, MO, SO, RO
[9]
November 2009 Soft-tissue sarcomas
GIST
Bone sarcomas
Conticanet,
Eurobonet
P. Casali, J.Y. Blay 44 15 – [10]
[11]
[12]
May 2010 NSCL cancer
SCL cancer
ESMO, San
Salvatore
Foundation
R. Stahel, E. Felip 38 15 PA, MD, MO, SO,
RO
[13]
[14]
September 2010 Colorectal cancer ESMO H.J. Schmoll,E. van
Cutsem,
A. Cervantes
37 22 PA, MO, SO, RO [15]
June 2011 Malignant lymphoma ESMO M. Ghielmini,
M. Dreyling
47 14 MO, HEM [16]
[17]
November 2011 Prostate cancer ESMO Horwich, V. Kataja 25 16 UR, MO, SO, RO [18]
January 2012 Soft-tissue sarcoma
GIST
Bone sarcoma
ESMO P. Casali, J.Y. Blay 41 16 EPI, PA, PHARM,
HEM, MO, SO,
RO
[19]
[20]
[21]
PA, pathology; MD, Medical Diagnostics; MO, Medical Oncology; SO, Surgical Oncology; RO, Radiation Oncology; HEM, Hematology; CM, Clinical
Medicine; ON, Oncology Nursing; ST, Statistics; PHARM, Pharmacy, Pharmacology; MP, Medical Policy; UR, Urology; EPI, Epidemiology.
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more constructive guidelines capable of facilitating medical
oncologists’ decision-making in daily practice.
The ESMO GLWG SOP include the organization of two
CCs per year on the basis of proposals from the Subject
Editors.
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appendix 1.
duties of the chairs of consensus conferences
(CCs)
(i) Appoint CC members (template letter of invitation).
(ii) Deﬁne guideline subtopics and organize Working
Groups (WGs) and their coordinators to process each
subtopic.
(iii) Collect and evaluate conﬂict of interest (COI) statements
from all the CC members.
(iv) Deﬁne deadlines for each step of the guideline
production process.
(v) Liaise with the WGs and Coordinators, all the CC
members, the Guidelines Working Group (GLWG) and
the ESMO administration.
(vi) Chair, moderate and conclude the CC.
(vii) Delegate to each WG the production of a draft
manuscript (with Questions, Recommendations and
Levels of Evidence) for the subtopic assigned.
(viii) Collect the draft manuscripts (with Questions,
Recommendations and Levels of Evidence) from WGs
and write up both the Full Version and Pocket Version
of the Clinical Practice Guidelines (CPGs).
(ix) Prepare a list of authors with the following being listed
before the abstract in this order: Chair, WG chairs
(alphabetical), Subject Editor (co-chair).
(x) Circulate the manuscript to all the members of the CC
for ﬁnal comments.
(xi) Obtain approval of the manuscript document from the
GLWG.
(xii) Finalize the manuscript after the ﬁnal round of
CC member feedback.
(xiii) Perform yearly minor updates of the CPG in
collaboration with all the CC members.
(xiv) Evaluate need for and request major updates of the CPG
(reiteration of the whole production cycle) to the ESMO
GLWG.
appendix 2.
duties of CC members, WGs and coordinators
(i) Liaise with the chairs, their WG fellow members and
WG coordinators.
Annals of Oncology editorial
Volume 23 | Supplement 7 | October 2012 doi:10.1093/annonc/mds222 | vii
(ii) Provide detailed COI statements.
(iii) Each WG coordinator should delegate tasks to his/her
WG members and organize joint work such as:
- Search string, search methods of PubMed, ASCO,
ESMO congress databases;
- Rules for acceptance of relevant evidence;
- Study of identiﬁed evidence;
- Production of the report on the questions and
evidence review including a list of important
references for the subtopic assigned.
(iv) Interact with WG members by e-mail and through
e-meetings.
(v) Each coordinator should forward the WG report on the
questions and evidence review to the CC chairs before
the CC.
(vi) All the CC members should attend the CC and present
and debate their reports.
(vii) Following the CC, each WG should produce a draft
manuscript (with Questions, Recommendations and
Levels of Evidence) taking into account the debate/
comments and forward it to the chairs.
(viii) Provide feedback to the Full Version and Pocket Version
of the CPG written up by the Chairs.
(ix) Participate in the yearly minor update of the
CPG organized by the chairs by e-mail or through e-
meetings.
appendix 3.
duties of GLWG and ESMO administration
(i) Deﬁne two CCs to take place per year.
(ii) Appoint the two chairs of each CC which will
produce the Consensus manuscript.
(iii) Along with the CC Chairs, approve CC synthesis
and evaluate all the COI statements.
(iv) Decide on the date and venue (along with chairs) and
organize logistics/support for each CC.
(v) Approve the Full Version and Pocket Version of the
CPG produced by the CC.
(vi) Approve the yearly minor updates of the CPGs produced
by each CC.
(vii) Decide whether there is need for major updates of a
CPG (reiteration of the whole production cycle),
autonomously or after suggestion by chairs.
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